Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds
Draft Report From Pricing Watchdog Calls Out Wegovy, Saxenda
Executive Summary
Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.
You may also be interested in...
ICER’s New President On What She Wants From Industry – And From Medicare Price Negotiations
In an interview, Sarah Emond talks about why she is ‘worried’ about cell and gene therapy, when ICER might revise its assessment of obesity drugs, and how CMS could build a reliable and transparent Medicare price negotiation program.
What’s Next For ICER: An Interview With New President Sarah Emond
The Institute for Clinical and Economic Review’s new president talked to Scrip in an interview about cell and gene therapy, obesity drugs and the new Medicare drug price negotiation program.
SELECT: Novo Nordisk Comes Roaring Back
After being whipped repeatedly by Lilly’s Mounjaro, Novo’s Wegovy smashes its obesity cardiovascular outcomes trial.